|1.||Ji, Jiuping: 1 article (06/2015)|
|2.||Ames, Matthew M: 1 article (06/2015)|
|3.||Rausch, Linda L: 1 article (06/2015)|
|4.||Samuelsson, Steven J: 1 article (06/2015)|
|5.||Lawrence, Scott M: 1 article (06/2015)|
|6.||Parman, Toufan: 1 article (06/2015)|
|7.||Altera, Kenneth P: 1 article (06/2015)|
|8.||Bunin, Deborah I: 1 article (06/2015)|
|9.||Buhrow, Sarah A: 1 article (06/2015)|
|10.||Davis, Myrtle: 1 article (06/2015)|
11/01/1989 - "Activity of batracylin (NSC-320846) against solid tumors of mice."
09/01/1988 - "Batracylin also caused regression of advanced (400 mg) colon 38 tumors. "
09/01/1988 - "Therapeutic efficacy against this subcutaneously implanted tumor was retained upon oral administration of Batracylin although, compared to ip treatment, larger doses were required. "
10/01/2013 - "Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas."
11/01/1989 - "Batracylin (NSC 320846) is a water insoluble, solid tumor active compound discovered by the Development Therapeutics Program of the National Cancer Institute (NCI). "
10/01/2013 - "However, due to unexpected cystitis, not preventable by hydration, and in the absence of a stronger signal for antitumor activity, further development of batracylin has been stopped."
06/01/2015 - "Batracylin (NSC-320846) is a dual inhibitor of DNA topoisomerases I and II. Batracylin advanced as an anticancer agent to Phase I clinical trials where dose limiting hemorrhagic cystitis (bladder inflammation and bleeding) was observed. "
06/01/2015 - "After a single oral administration of 16 or 32 mg/kg, the majority of batracylin was converted to N-acetylbatracylin (NAB) with a half-life of 4 hr to 11 hr. Mesna (Mesnex™), a drug known to reduce the incidence of hemorrhagic cystitis induced by ifosfamide or cyclophosphamide, was administered to rats prior to batracylin, but did not alleviate batracylin-induced bladder and renal toxicity. "
11/01/1989 - "In vivo we have tested batracylin against mammary adenocarcinoma 16/C, colon 9, colon 38, colon 51, Panc 03, and hepatoma 129. "
09/01/1988 - "Batracylin (NSC 320846, BAY H 2049), given ip on days 2 and 9 at a dose 400 mg/kg, inhibited tumor growth completely in 80-100% of mice with early-stage colon adenocarcinoma 38. "
|5.||Melanoma (Melanoma, Malignant)
03/13/2003 - "Preliminary screening data obtained at the National Cancer Institute (NCI, Bethesda, MD) have revealed that the conjugates did not expose any cytotoxic activity even at 10(-4)-10(-8) M or microg/mL. During tests performed at Medical University of Gdansk, Poland, two analogues 11c and 11e reduced the proliferation of Ab melanoma cells in vitro compared with batracylin alone (Table 2, Figure 1)."
|3.||Mesna (Coenzyme M)
|5.||Dihydrotachysterol (AT 10)